Florida (USA) based biological startup Salveo Agro announced that it has received an investment from Swiss investment firm Zentia AG. This is an initial stage investment in the biological crop control firm and allows the European firm to be considered an early investor and have a material ownership stake.
The amount of the deal was not disclosed, although it was noted that Zentia will also support Salveo Agro's ambition to expand the application of its patented natural ingredient-based technology to tackle a broad spectrum of plant pathogens, as well as to act as a potent biostimulant for high-value crops.
Together with its partners and investors, Salveo Agro's strategy is to demonstrate that its Tectus Matrix® technology, already proven to be highly effective in treating Black Sigatoka and Panama Disease in banana, is also a sustainable and disruptive technology that addresses a broader spectrum of pathogens (including bacteria). It is a rapidly scalable solution suitable for global use.
Según Jack Bracewell, director general de Salveo Agro, “estamos muy satisfechos de que Zentia se una a nuestro grupo de propietarios con esta inversión. Zentia es un inversor profesional y competente que se caracteriza por una perspectiva de inversión a largo plazo”.
For Zentia, the investment into Salveo Agro is based on a wish to invest in companies that contribute to a sustainable development in the world.
